This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Past Earnings Performance

We're still processing the latest earnings report of this company

Past criteria checks 0/6

MorphoSys's earnings have been declining at an average annual rate of -29%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 8.5% per year.

Key information

-29.0%

Earnings growth rate

-27.9%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	8.5%
Return on equity	n/a
Net Margin	-198.2%
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How MorphoSys makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HMSE:MOR Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	250	-495	345	304
31 Mar 24	241	-469	337	294
31 Dec 23	238	-190	147	274
30 Sep 23	223	104	128	271
30 Jun 23	255	100	133	286
31 Mar 23	261	-61	130	290
31 Dec 22	278	-151	153	290
30 Sep 22	250	-861	143	289
30 Jun 22	195	-851	156	276
31 Mar 22	174	-596	178	255
31 Dec 21	180	-514	180	224
30 Sep 21	163	-150	196	191
30 Jun 21	143	-103	191	160
31 Mar 21	124	-177	175	151
31 Dec 20	328	98	159	125
30 Sep 20	303	64	140	104
30 Jun 20	293	105	107	96
31 Mar 20	309	153	75	90
31 Dec 19	72	-103	59	107
30 Sep 19	71	-96	42	101
30 Jun 19	114	-42	35	94
31 Mar 19	87	-59	31	95
31 Dec 18	76	-56	28	87
30 Sep 18	94	-27	25	85
30 Jun 18	54	-82	23	101
31 Mar 18	58	-74	21	98
31 Dec 17	67	-70	21	103
30 Sep 17	52	-84	17	106
30 Jun 17	49	-73	16	94
31 Mar 17	49	-68	15	90
31 Dec 16	50	-60	16	84
30 Sep 16	49	-45	15	81
30 Jun 16	48	-40	15	78
31 Mar 16	48	-33	15	79
31 Dec 15	106	15	15	75
30 Sep 15	111	27	14	64
30 Jun 15	116	33	14	62
31 Mar 15	119	37	14	55
31 Dec 14	64	-3	14	52
30 Sep 14	61	-6	16	53
30 Jun 14	60	-5	17	48
31 Mar 14	77	7	18	48
31 Dec 13	78	7	18	48

Quality Earnings: MOR is currently unprofitable.

Growing Profit Margin: MOR is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MOR is unprofitable, and losses have increased over the past 5 years at a rate of 29% per year.

Accelerating Growth: Unable to compare MOR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).

Return on Equity

High ROE: MOR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/11/21 05:23
End of Day Share Price	2024/10/15 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MorphoSys AG is covered by 35 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Olav Zilian	Baader Helvea Equity Research
Brian Balchin	Barclays
Rosie Turner	Barclays